Spruce Biosciences on Track for Q4 2026 BLA Submission for Sanfilippo Syndrome Treatment — Spruce Biosciences, Inc.

Event summary

Spruce Biosciences completed pre-BLA meetings with the FDA, confirming its plan to submit a BLA for TA-ERT in Q4 2026.
FDA found the company's drug substance and drug product analytical comparability strategies reasonable following technology transfer to a commercial-scale manufacturer.
The company and FDA aligned on the overall content and format of the planned BLA, including the structure of integrated efficacy and safety summaries.
Spruce successfully completed the manufacturing of the first PPQ batch in July 2026 and is on track to complete the second PPQ batch in Q4 2026.

The big picture

Spruce Biosciences' progress in its pre-BLA meetings with the FDA marks a significant milestone in the development of TA-ERT for Sanfilippo Syndrome Type B, an ultra-rare and fatal genetic disease with no current FDA-approved therapies. The company's alignment with the FDA on key aspects of the BLA submission underscores the strategic importance of this collaboration. The successful transfer of manufacturing to a commercial-scale manufacturer and the completion of the first PPQ batch further strengthen Spruce's position as it prepares for potential approval and commercial launch.

What we're watching

Regulatory Pathway: Whether the FDA's accelerated approval pathway based on reduction of CSF HS-NRE will be sufficient for TA-ERT's approval.
Manufacturing Readiness: The pace at which Spruce can complete the second PPQ batch and other CMC activities to support the BLA submission.
Commercialization Strategy: How Spruce plans to commercialize TA-ERT if approved, given the ultra-rare nature of Sanfilippo Syndrome Type B.